S
Scott Moseley
Researcher at Alexion Pharmaceuticals
Publications - 16
Citations - 669
Scott Moseley is an academic researcher from Alexion Pharmaceuticals. The author has contributed to research in topics: Asfotase alfa & Hypophosphatasia. The author has an hindex of 9, co-authored 15 publications receiving 502 citations.
Papers
More filters
Journal ArticleDOI
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Michael P. Whyte,Michael P. Whyte,Cheryl Rockman-Greenberg,Keiichi Ozono,Richard Riese,Scott Moseley,Agustin Melian,David D. Thompson,Nick Bishop,Nick Bishop,Christine Hofmann +10 more
TL;DR: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.
Journal ArticleDOI
Asfotase alfa therapy for children with hypophosphatasia.
Michael P. Whyte,Katherine L Madson,Dawn Phillips,Amy Reeves,William H. McAlister,Amy Yakimoski,Karen E. Mack,Kim Hamilton,Kori Kagan,Kenji P Fujita,David D. Thompson,Scott Moseley,Tatjana Odrljin,Cheryl Rockman-Greenberg,Cheryl Rockman-Greenberg +14 more
TL;DR: Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP and no evidence emerged for clinically important ectopic calcification or treatment resistance.
Journal ArticleDOI
Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Priya S. Kishnani,Cheryl Rockman-Greenberg,Frank Rauch,M. Tariq Bhatti,Scott Moseley,Andrew Denker,Eric Watsky,Michael P. Whyte,Michael P. Whyte +8 more
TL;DR: It is suggested that in adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa is associated with normalization of circulating TNSALP substrate levels and improved functional abilities.
Journal ArticleDOI
Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.
Michael P. Whyte,Michael P. Whyte,Jill H. Simmons,Scott Moseley,Kenji P Fujita,Nick Bishop,Nada J. Salman,John W. Taylor,Dawn Phillips,Mairead McGinn,William H. McAlister +10 more
TL;DR: Patients with perinatal or infantile hypophosphatasia treated with asfotase alfa for up to 7 years showed early, sustained improvements in skeletal mineralisation and weight Z scores improved to within normal range from year 3 to study end; length or height Z scoresImproved but remained below normal.
Journal ArticleDOI
Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys.
TL;DR: The health profile of patients responding on the SF-12 showed a broad and substantial impact of HPP on health-related quality of life, with domains related to physical ability showing the greatest decrement compared to normative data.